Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)

Market Cap	8.79B -6.7%
Revenue (ttm)	15.94B -1.7%
Net Income	449.15M -26.7%
EPS	0.18 -25.1%
Shares Out	2.52B
PE Ratio	19.46
Forward PE	13.42
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,493,562
Average Volume	30,810,241
Open	3.560
Previous Close	3.570
Day's Range	3.480 - 3.570
52-Week Range	3.060 - 4.150
Beta	0.21
RSI	53.80
Earnings Date	Apr 23, 2026

About SHA:600664

Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cerebrovascular, and cardiovascular diseases, as well as mineral and nutritional supplements, Chinese medicines, and antibiotics. It also provides calcium ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1991
• Employees: 10,180
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600664

Financial Performance

In 2024, SHA:600664's revenue was 16.18 billion, an increase of 4.65% compared to the previous year's 15.46 billion. Earnings were 628.85 million, an increase of 59.10%.